177Lu-PSMA radioligand therapy for prostate cancer
177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinic...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 1, 2017
|
| In: |
Journal of nuclear medicine
Year: 2017, Volume: 58, Issue: 8, Pages: 1196-1200 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.117.191023 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.2967/jnumed.117.191023 Verlag, kostenfrei, Volltext: https://jnm.snmjournals.org/content/58/8/1196 
|
| Author Notes: | Wolfgang P. Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, and Matthias Eiber |
| Summary: | 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer. |
|---|---|
| Item Description: | Die Zahl 177 ist im Titel hochgestellt Gesehen am 23.12.2020 |
| Physical Description: | Online Resource |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.117.191023 |